CELC Celcuity (CELC) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-medical laboratories · CIK 0001603454
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
167
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $57.7K priced
What the filings say about CELC
Insiders, 180 days
-$322.5M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Celcuity insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Celcuity Inc. insiders sold a net $322.5M of stock across 66 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 59.0% of the 442,940 shares held after it.
- No other insider sold within 30 days.
- 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider BAKER BROS. ADVISORS LP sold about $26.8M of CELC on Jul 14, 2026, the largest insider sale at the company on our record; 167 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 64.9% of the 4,372,852 shares held after it.
- No other insider sold within 30 days.
- 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider BAKER BROS. ADVISORS LP sold about $291.0M of CELC on Jul 14, 2026, the largest insider sale at the company on our record; 167 funds added in the latest 13F quarter.Context
- 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Jan 27, 2026.
- The trade is 38.5% of the 65,000 shares held after it.
- 1 other insider sold within 30 days.
- 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Dalvey David sold about $3.5M of CELC on May 4, 2026, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 167 funds added in the latest 13F quarter.Context
- 33 earlier Form 4 trades (code P or S) here by this insider (33 sales), the last on Mar 31, 2026.
- The trade is 39.6% of the 7,125 shares held after it.
- 1 other insider sold within 30 days.
- 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Buller Richard E sold about $401.3K of CELC on May 4, 2026; 1 other insider sold within 30 days and 167 funds added in the latest 13F quarter.Context
- 33 earlier Form 4 trades (code P or S) here by this insider (33 sales), the last on Mar 31, 2026.
- The trade is 23.1% of the 9,950 shares held after it.
- 1 other insider sold within 30 days.
- 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Buller Richard E sold about $324.5K of CELC on May 4, 2026; 1 other insider sold within 30 days and 167 funds added in the latest 13F quarter.66 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$322.5M over 180 days
below 94% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
167 funds bought in last quarter
more than 71% of Healthcare Services
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
37.0% of the float short (float per yahoo 2026-10-26) · 11.0 days to cover · settled 2026-09-30
more than 98% of Healthcare Services
What changed in the last 30 days
Oct 27Insider selling stopped: no sales in 90 days after 9 in the prior 90
Why it matters
The absence is the signal: 9 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch CELC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-6.8%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CELC: institutional holders (13F)
13F holdings, latest reported quarter
7,915,792 sh
$828.2M
3,400,000 sh
$355.7M
3,304,903 sh
$345.8M
3,197,200 sh
$334.5M
3,018,785 sh
$315.8M
Congress trades in CELC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CELC planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
667, L.P.
Filed 2026-07-14
$26.8M
Baker Brothers Life Sciences, L.P.
Filed 2026-07-14
$291.0M
CELC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Jacob Discovery Fund
$878.2K position · as of 2026-05-31
5.5%
ALPS Medical Breakthroughs ETF
$6.3M position · as of 2026-05-31
3.9%
Tema Oncology ETF
$6.3M position · as of 2026-05-31
3.6%
Nomura Small Cap Growth Fund
$14.4M position · as of 2026-06-30
1.2%
SFT Nomura Small Cap Growth Fund
$2.4M position · as of 2026-06-30
1.2%
Nomura VIP Small Cap Growth Series
$2.8M position · as of 2026-06-30
1.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 3
2 active
1
Not applicable
0 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Brian F. Sullivan
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$16.4M
$63.0M
$3.8M
+612%
n/a
2024
$6.6M
$5.2M
$1.5M
-7%
n/a
2023
$1.7M
$2.5M
$1.2M
+4%
n/a
2022
$1.8M
$2.5M
$599.4K
+6%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $322.5M sold by insiders over 180 days, 167 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CELC financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM CELC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM CELC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$192.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CELC
| FY Dec 2025 | -$153.5M |
| FY Dec 2024 | -$83.7M |
| FY Dec 2023 | -$53.9M |
| FY Dec 2022 | -$36.2M |
| FY Dec 2021 | -$20.4M |
| Jun 2026 | -$55.5M |
| Mar 2026 | -$55.3M |
| Dec 2025 | -$36.5M |
| Sep 2025 | -$44.9M |
| Jun 2025 | -$36.3M |
| Mar 2025 | -$35.9M |
| Dec 2024 | -$27.8M |
| Sep 2024 | -$20.6M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity CELC
| FY Dec 2025 | 1.37x |
| FY Dec 2024 | 0.91x |
| FY Dec 2023 | 0.27x |
| FY Dec 2022 | 0.27x |
| FY Dec 2021 | 0.23x |
| Jun 2026 | n/a |
| Mar 2026 | 2.58x |
| Dec 2025 | 1.37x |
| Sep 2025 | 1.17x |
| Jun 2025 | 2.38x |
| Mar 2025 | 1.22x |
| Dec 2024 | 0.91x |
| Sep 2024 | 0.70x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-32,882.68x
TTM operating cash flow over long-term 2026-06-30 plus current 2021-06-30 (60 months older than the period end)
Cash flow to debt CELC
| FY Dec 2025 | -1.11x |
| FY Dec 2024 | -0.79x |
| FY Dec 2023 | -1.43x |
| FY Dec 2022 | -1.01x |
| FY Dec 2021 | -1.27x |
| Jun 2026 | -32,882.68x |
| Mar 2026 | -1.25x |
| Dec 2025 | -1.11x |
| Sep 2025 | -1.05x |
| Jun 2025 | -1.14x |
| Mar 2025 | -0.97x |
| Dec 2024 | -0.79x |
| Sep 2024 | -0.71x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-1,434%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CELC
| FY Dec 2025 | -163.8% |
| FY Dec 2024 | -87.5% |
| FY Dec 2023 | -46.6% |
| FY Dec 2022 | -39.9% |
| FY Dec 2021 | -73.6% |
| Jun 2026 | -1,434% |
| Mar 2026 | -275.2% |
| Dec 2025 | -163.8% |
| Sep 2025 | -122.0% |
| Jun 2025 | -134.5% |
| Mar 2025 | -115.4% |
| Dec 2024 | -87.5% |
| Sep 2024 | -77.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-44.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CELC
| FY Dec 2025 | -49.8% |
| FY Dec 2024 | -51.2% |
| FY Dec 2023 | -34.8% |
| FY Dec 2022 | -30.9% |
| FY Dec 2021 | -59.9% |
| Jun 2026 | -44.8% |
| Mar 2026 | -61.4% |
| Dec 2025 | -49.8% |
| Sep 2025 | -43.4% |
| Jun 2025 | -62.5% |
| Mar 2025 | -62.6% |
| Dec 2024 | -51.2% |
| Sep 2024 | -45.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital CELC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-47.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CELC
| FY Dec 2025 | -54.2% |
| FY Dec 2024 | -58.0% |
| FY Dec 2023 | -38.3% |
| FY Dec 2022 | -31.2% |
| FY Dec 2021 | -59.6% |
| Jun 2026 | -47.2% |
| Mar 2026 | -66.4% |
| Dec 2025 | -54.2% |
| Sep 2025 | -46.6% |
| Jun 2025 | -70.4% |
| Mar 2025 | -71.2% |
| Dec 2024 | -58.0% |
| Sep 2024 | -51.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CELC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$3.0B
market value at close 2026-10-23 on 2026-08-05 shares, plus long-term 2026-06-30 plus current 2021-06-30 (60 months older than the period end), minus cash 2026-06-30
Enterprise value CELC
| FY Dec 2025 | $4.6B |
| FY Dec 2024 | $568.6M |
| FY Dec 2023 | $359.5M |
| FY Dec 2022 | $227.8M |
| FY Dec 2021 | $128.4M |
| Jun 2026 | $4.9B |
| Mar 2026 | $5.5B |
| Dec 2025 | $4.6B |
| Sep 2025 | $2.2B |
| Jun 2025 | $564.8M |
| Mar 2025 | $471.4M |
| Dec 2024 | $568.6M |
| Sep 2024 | $644.3M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-6.0%
TTM free cash flow over market value at close 2026-10-23
FCF yield CELC
| FY Dec 2025 | -3.3% |
| FY Dec 2024 | -17.2% |
| FY Dec 2023 | -15.3% |
| FY Dec 2022 | -16.7% |
| FY Dec 2021 | -10.4% |
| Jun 2026 | -3.8% |
| Mar 2026 | -3.1% |
| Dec 2025 | -3.3% |
| Sep 2025 | -6.9% |
| Jun 2025 | -23.9% |
| Mar 2025 | -26.8% |
| Dec 2024 | -17.2% |
| Sep 2024 | -13.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CELC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$172.2M | -$113.3M | -$66.2M | -$39.4M |
| Net income | -$177.0M | -$111.8M | -$63.8M | -$40.4M |
| EPS (diluted) | -3.79 | -2.83 | -2.69 | -2.64 |
| Operating cash flow | -$153.3M | -$83.5M | -$53.8M | -$36.0M |
| Cash | $165.7M | $22.5M | $30.7M | $24.6M |
| Long-term debt | $137.5M | $105.1M | $37.6M | $35.8M |
SEC XBRL, fiscal years, as known on 2026-10-27
CELC Stock Sonar score 5/7 axes
Find similar shapesCompareCELC ranks highest on institutional and government (71st percentile) and profitability (11th), and lowest on financial health (1st), among Healthcare Services peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CELC filings, in plain words
Are Celcuity insiders buying or selling CELC?
In the 180 days to 2026-10-27, Celcuity insiders were net sellers, a net $322.5M across purchases and sales reported on Form 4, by 3 sellers.
Read the full summary
In the 180 days to 2026-10-27, Celcuity insiders were net sellers of CELC, a net $322.5M across purchases and sales reported on Form 4 by 3 sellers. None of the 9 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
